The "Answer" to CancerThe Neoantigen Revolution. The field of cancer therapy has been transformed in less than a decade by the approval of checkpoint inhibitors, the advent of next-generation sequencing (NGS) methods for identifying tumor mutations, and the...
Results for "ancer"
Neoadjuvant personalized cancer vaccines: the final frontier?
EpiVax, Inc. Subsidiary, EpiVax Therapeutics Signs Exclusive Collaboration Agreement with GreenLight Biosciences to Develop Personalized Cancer Vaccines
EpiVax, Inc. is excited to announce that its subsidiary, EpiVax Therapeutics, has signed an exclusive collaboration agreement with GreenLight Biosciences to advance the development of personalized cancer vaccines. The effort will combine GreenLight’s mRNA design and...
Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy
Improving Cancer Survival Prediction: A New Approach with EpiVax Therapeutics’ Ancer Platform
PROVIDENCE, RI, May 13, 2021 /PRNewswire/ -- EpiVax Therapeutics, Inc. (“EVT”) announces the publication “Multi‑step screening of neoantigens’ HLA and TCR‑interfaces improves prediction of survival” in Scientific Reports. This study demonstrates a superior method of...
FDA Webinar: Epitope Selection for Cancer Vaccines
EpiVax CEO/CSO Annie De Groot hosted a talk for the FDA Office of Tissues and Advanced Therapies (OTAT) group on February 11, 2021. Annie presented the latest on EpiVax's iVAX Toolkit in her talk "Epitope Selection for Cancer Vaccines". JanusMatrix, our tool for...
Press Release: EpiVax Oncology Inc. Announces It Has Reduced the Timeline of Its Personalized Neoantigen Therapeutic Cancer Vaccine Process to Under Four Weeks
March 26, 2020 04:42 PM Eastern Daylight Time NEW YORK--(BUSINESS WIRE)--EpiVax Oncology, Inc., a precision cancer immunotherapy company, today announced it has reduced the timeline from biopsy to vaccine to under 4 weeks for its personalized neoantigen therapeutic...
Highly efficient selection of tumor neoantigens improves therapeutic cancer vaccine efficacy
Highly efficient selection of tumor neoantigens improves therapeutic cancer vaccine efficacy
Integrating CD8 and CD4 effector neo-epitope content with regulatory T cell epitope exclusion is a superior prognostic biomarker for bladder cancer patients compared to their tumor mutation burden
EpiVax_Oncology_SITC19_BLCA_06Nov19_50Wx36H
International Cancer Immunotherapy Conference September 25th-28th
5th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference CICON 2019: Translating Science into Survival Wednesday, September 25 - Saturday, September 28 Espace Grande Arche de la Defense Parvis de la Défense 92044 Paris, France Members of EpiVax...